CANTA — Cantargia AB Share News
0.000.00%
Last trade - 00:00- SEK533.52m
- SEK275.49m
- SEK316.70m
Brief: Cantargia FY EBIT SEK -290 Million
Brief: Cantargia Reports U.S. Regulatory Approval To Start Pancreatic Cancer Phase IIb Trial With Nadunolimab
Brief: Cantargia Reports New Preclinical Data Confirming Potential Of Nadunolimab, Can10
Brief: Third Party Withdraws Appeal Related To Cantargia Patent
Brief: Cantargia 9M EBIT SEK -218.9 Million
Brief: Cantargia Presents Positive Phase Ib Data In Breast Cancer Drug Study
Brief: Cantargia Clinical Data On Nadunolimab In Triple-Negative Breast Cancer Shows Combination Therapy Well Tolerated
Brief: Cantargia - Third Party Appeals EPO Decision On Cantargia Patent
Brief: Cantargia Presents New Preclinical Data On Nadunolimab
Brief: Cantargia Announces New Nadunolimab Clinical Trial In Leukemia Financed By External US Grant
Brief: Cantargia's CAN10 For Treatment Of Systemic Sclerosis Gets Orphan Drug Designation From FDA
Brief: Cantargia H1 EBIT at SEK -140.2 Million
Brief: Cantargia Receives Regulatory Approval For Phase I Trial For CAN10
Brief: Cantargia Reports Favorable Outcome Of Patent Oppositions In Europe
Brief: Cantargia Appoints Patrik Renblad As CFO
Brief: Cantargia To Present Promising Nadunolimab Efficacy In Non-Small Cell Lung Cancer
Brief: Cantargia Q1 Operating Loss Narrows To SEK 77.6 Mln
Brief: Cantargia Intensifies Development Of Nadunolimab In Pancreatic Cancer With Controlled Phase IIb Clinical Trial
Brief: Cantargia Presents Positive Results For Nadunolimab At Aacr 2023 Including New Clinical Data In Pancreatic Cancer